



# ICE25

International Conference on Endourology

6-8 November 2025, Rome, Italy

[www.ICE25.org](http://www.ICE25.org)

 Endourology  European Association of Urology

## Abstract submission deadline

The deadline for abstract submission for poster presentations is **5 August 2025, 23:59:59 Central European Time (CEST)**. Please submit your abstract in time to avoid any issues caused by technical difficulties. Make sure to use the latest version of Google Chrome.

Until this deadline you will be able to:

- make changes in your abstract or author list, even when already submitted
- withdraw your abstract(s)

After this submission deadline:

- there is **no possibility to edit abstracts anymore**
- to withdraw your submitted abstracts you should send an email before 22 September 2025 to [abstracts@congressconsultants.com](mailto:abstracts@congressconsultants.com)

After 22 September 2025 your abstract (if accepted by the SCO and not withdrawn by you) will be published in the EU Journal's Supplement and you can only decline the presentation, not withdraw the abstract anymore.

Only abstracts submitted through the official online submission system will be considered. Please note, there is no option for late-breaking abstract submission.

## Rules & regulations related to publication of abstracts

- Abstract(s) should not have been **published or presented** before the start of ICE25.
- All sources of financial support (including government grants or companies which handled the data) must be listed in the assigned answering box as part of the submission procedure (and not in the abstract text). All grant funding agencies and/or company abbreviations should be spelled out. This information will be published with the full body abstract, wherever it is reproduced on the EAU's publications, channels or online.
- Accepted abstracts and author lists will be published as submitted, except for a simple English spelling check.

### Copyright

- Copyright of the accepted abstract is assigned to the European Association of Urology and any conflict with any other scientific association will be the sole responsibility of the author(s).
- All abstracts that are published, including figures and tables, are the property of EAU and are protected by copyright.
- Requests for re-use of material can be done by sending an email to [abstracts@congressconsultants.com](mailto:abstracts@congressconsultants.com) (please include the abstract code).
- By submitting an abstract you agree (also on behalf of co-authors) to the terms of use and conditions as stated above. Please note that transfer of copyright to the EAU applies to all materials derived from the abstract submitted (such as posters, videos, slide/audio presentations, live-streams, webcasts and all other materials).

- Copyright can be shared with companies for a maximum duration of 1 year, these requests have to be made written to [sales@uroweb.org](mailto:sales@uroweb.org) and come with a cost.

### Publications

- Accepted abstracts will be published in a Supplement of the European Urology Journal prior to the congress.
- By submitting an abstract you agree (also on behalf of (co-)authors) that the accepted abstract as well as related materials such as videos, slide/audio presentations, live-streams, webcasts, poster PDFs and any other materials are published in European Urology and other EAU publications and media channels.

## Rules related to abstract submission

### Content-related instructions

#### Clinical Studies

In clinical studies, the authors must state that an Ethical Committee approval has been obtained.

Please note that the statement should clearly indicate whether the approval was obtained or not, accompanied by a brief explanation of the reason in case of a disapproval. This information is necessary for the proper processing of the review.

#### Case reports

Only high quality case reports based on a systematic review, which is based on raw data with a clearly defined protocol, are allowed. Other case reports are not eligible for submission.

#### Human experimentation

Any human experimentation conducted with respect to the submitted abstract(s), should have been conducted according to the protocol approved by the institutional or local committee on ethics in human investigation; or, if no such committee exists, the works should have been conducted in accordance with the principles of the Declaration of Helsinki of World Medical Association. Council may enquire further into ethical aspects when evaluating the abstract(s).

#### Systematic reviews

Systematic reviews (with or without meta-analysis) can be submitted only when they meet the following standards:

- The clinical question was clearly defined using a standard PICO format
- A comprehensive systematic literature search was carried out
- An assessment of the risk of bias was made
- Key findings are clearly described including clinical practice relevance

#### Late breakers

There is no submission for late breaking abstracts

#### Topic

A topic has to be selected for your submission, the system will offer you a drop-down menu. For the review of the abstract, it is of vital importance that the correct (sub)topic, clinical step(s) and management tool(s) are selected.

All topic combinations available can be found on the website, [click here](#).

### Trial in progress

Trials in Progress abstracts offer researchers a platform to present ongoing trials, promote collaboration, and discuss correlatives and innovative trial designs. It is expected that abstracts submitted as Trial in progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Trial in Progress abstracts should contain the following two sections and should not have data analysis available before the submission deadline.

#### Introduction and objectives:

Provide the scientific background and rationale of the trial, highlighting correlative studies of interest.

#### Materials and methods:

Detail the trial design and statistical methods, emphasizing any innovative aspects. Outline the planned interventions and specify major eligibility criteria. Report current enrolment without disclosing protocol-specified results. State clinical trial registry number.

## Practical instructions

All abstracts must be submitted in **English**.

### Abstract Title

- The title should clearly define the topic.
- There is no maximum length for the title, but the characters in the title are included in your total character count.
- The first letter of the title will automatically begin with a capital letter.
- Standard abbreviations may be used as follows: on first use spell out the full term and follow with the abbreviation in parentheses.
- Do NOT mention your institution in the title.
- Do NOT type the abstract title in capital letters.
- Do NOT end the title with a dot.

### Authors and Affiliations

- A maximum of 24 authors per abstract is allowed.
- Each quoted author should have contributed substantially to the represented work in terms of conceptual design or analysis, writing of the article and final approval of the article in order to take public responsibility for the content.
- An abstract presenter is limited to 5 abstract presentations.
- Please make sure to write the name of the Organisation/Institution, Department, City and Country in English (one institution per author).
- If co-authors are from the same institution, the programme will automatically copy all information into the next boxes, so you do not have to type all information again. If co-authors are not from the same institution you can edit any box as you wish.
- There is only the possibility to enter one first author, one presenting author and one last author.
- Do type family name and full first name of all authors. Do NOT type titles, degrees and institutional affiliations. Carefully check the correct spelling of all names as this will be the way that names will be published.

### Abstract Body

- The following headers have already been formatted for you and should not be repeated in the text fields:
  - Introduction & objectives (*state the objective of the study*)
  - Materials & methods (*describe the material and methods*)
  - Results (*summarise the results presenting sufficient details to support the conclusions reached, it is NOT acceptable to state: "The results will be discussed"*).
  - Conclusion
- Use digits for numbers (example: 1 instead of one) and only very well-known abbreviations e.g., ml, kg, MRI.  
Standard abbreviations may be used as follows: on first use spell out the full term and follow with the abbreviation in parentheses.
- To insert tables use the 'Insert table'-icon.
- To insert symbols or specific characters use the 'Symbol-icon'. Do NOT copy/paste as this will cause format problems.  
To insert figures see explanation below.
- Any acknowledgements can be placed underneath the conclusion.

### Figures

- Upload of pictures/graphics is only possible as jpg file (counts for 500 characters).
- Upload of only 1 picture/graphic is allowed and a collage of multiple pictures is NOT allowed, because of readability. If not readable, it will be removed from the submission.
- How to upload a jpg file:
  - Click on the insert/edit image icon
  - To upload new image, click on upload -browse for an image
  - Select your image
  - Click on upload
  - Your selected image will be shown in the list of Uploaded Images
  - First select the image and click on 'Insert'
  - To resize your image, please click on 'Appearance' and adjust the dimensions

### Abstract Size

The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and pictures/graphics). The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. A picture/graphic counts for 500 characters.

### Proof reading

After you have inserted all data for your abstract submission a preview will show on your screen. Please verify that your abstract submission is correct and read this preview carefully (including author information). Keep a print for your own records.

It is the responsibility of the submitting author to ensure the abstract is in perfect order with no errors in spelling or grammar, as revisions will not be accepted. Abstracts will not be corrected.

### AI technology

Where authors use generative AI and AI-assisted technologies in the writing process, these technologies should only be used to improve readability and language of the work. Applying the technology should be done with human oversight and control and authors should carefully review and edit the result, because AI can generate authoritative sounding output that can be incorrect,

incomplete or biased. The authors are ultimately responsible and accountable for the contents of the work. Authors should disclose in their abstract the use of AI and AI-assisted technologies.

Authors should not list AI and AI-assisted technologies as an author or co-author, nor cite AI as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans. Authors are also responsible for ensuring that the work is original.

## **Abstract Review Process**

All abstracts are subject to peer review and are expected to meet the standards of academic/scientific excellence. Submissions will be reviewed by an expert panel whose identities will remain anonymous to the authors. Reviewers will give scores from 1 to 5 points, taking into consideration the following criteria: Originality, priority, quality of research methodology and data. Review and session composition will take place in the middle of August. The outcome of the abstract selection is available online through the abstract submission website on 29 August 2025. You will receive a notification by email. The Scientific Congress Office reserves the right to obtain your raw data for statistical evaluation.

For any questions please do not hesitate to contact the abstract handling team:  
[abstracts@congressconsultants.com](mailto:abstracts@congressconsultants.com).